Opendata, web and dolomites

H2020MM04 SIGNED

DC-based immunotherapy to treat Malignant Mesothelioma

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 H2020MM04 project word cloud

Explore the words cloud of the H2020MM04 project. It provides you a very rough idea of what is the project "H2020MM04" about.

13    poor    24    time    threats    malignant    exposed    combination    massively    union    2065    16    deaths    fibres    prospects    first    curative    netherlands    personalised    ema    therapy    orphan    12    despite    mc    quantities    asbestos    january    2012    pulmonary    treatments    banned    mm    mesothelioma    care    cell    approval    aggressive    consisting    1229    autologous    06    dendritic    market    workers    granted    2010    chemotherapy    resolution    death    therapeutic    registration    treatment    months    inhalation    standard    iarc    consumers    pemetrexed    last    abolishing    fda    occupational    health    allogeneic    prolonged    protecting    cisplatin    designation    risk    environment    immuno    actions    scientific    international    extremely    millions    tumour    clinical    pulsed    twice    events    illness    carcinogens    considerably    survival    tremendously    rotterdam    median    adverse    ini    incidence    immunotherapy    signs    cells    disease    extensive    limited    erasmus    treat    history    diseases    fatal    2014    trial    date    lysate    resistant    reported   

Project "H2020MM04" data sheet

The following table provides information about the project.

Coordinator
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM 

Organization address
address: DR MOLEWATERPLEIN 40
city: ROTTERDAM
postcode: 3015 GD
website: www.erasmusmc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website https://www.denimstudy.eu/
 Total cost 5˙782˙965 €
 EC max contribution 5˙782˙965 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2015-two-stage
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) coordinator 2˙375˙146.00
2    UNIVERSITA POLITECNICA DELLE MARCHE IT (ANCONA) participant 669˙452.00
3    STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS NL (AMSTERDAM) participant 669˙451.00
4    UNIVERSITY OF LEICESTER UK (LEICESTER) participant 669˙215.00
5    UNIVERSITAIR ZIEKENHUIS ANTWERPEN BE (EDEGEM) participant 668˙874.00
6    CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE FR (LILLE) participant 659˙822.00
7    AMPHERA BV NL (DEN BOSCH) participant 48˙000.00
8    EUROPEAN CANCER PATIENT COALITION BE (BRUXELLES) participant 23˙000.00

Map

 Project objective

Asbestos is one of the major occupational carcinogens. The European Union has an extensive history of protecting workers and consumers against asbestos and even adopted a resolution 2012/2065(INI) ‘on asbestos related occupational health threats and prospects for abolishing all existing asbestos’ last year. Although asbestos is banned, it is still massively present in the built environment. Millions of workers & consumers in the EU were, and still are, for many years exposed to asbestos fibres, despite all measures.

Inhalation of even very low quantities of asbestos fibres tremendously increases the risk of developing Malignant Mesothelioma (MM). The IARC reported 8.100 MM deaths in 2010 in the EU. Despite all EU actions, MM incidence is still increasing. MM is a highly fatal disease with a poor median survival time from first signs of illness to death around 12 months despite aggressive treatments. To date there is no curative therapy for MM. MM is considered as an extremely therapy-resistant disease. Chemotherapy consisting of a combination of pemetrexed and cisplatin is considered standard of care with a median survival increase of 3 months (9-12 months).

The department of pulmonary diseases of the Erasmus MC, Rotterdam, The Netherlands, in collaboration with international partners, have developed a promising personalised immunotherapy for MM with very limited adverse effects. The first clinical results show a considerably prolonged average survival with limited adverse events (24 months, twice as long).

The EMA and the FDA granted this therapy Orphan Designation: autologous dendritic cells pulsed with allogeneic tumour cell lysate for the treatment of malignant mesothelioma (EU: 16 January 2014 - EU/3/13/1229; FDA – US: 06 May 2014).

The objective for the project is to deliver the scientific & registration package for market approval by the EMA of a novel immuno therapeutic approach to treat MM. This includes the execution of a phase II/III clinical trial.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "H2020MM04" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "H2020MM04" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More